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O n 31 March 1998, the U.S.
Environmental Protection Agency
(EPA) issued a Notice of Data
Availability in the Federal Register to raise
the drinking water maximum contaminant
level goal (MCLG) for chloroform, a sus-
pected human carcinogen, from zero to
300 parts per billion (ppb). MCLGs,
which are required under the Safe
Drinking Water Act (SDWA), are nonen-
forceable goal levels under which no
adverse human health effects are expected.
By contrast, maximum contaminant levels
(MCLs) are enforceable standards that
take issues of technical feasibility and
compliance costs into account. MCLs are
set as close to the MCLG as possible. By
proposing to raise the MCLG, the EPA
departed from its long-held default
reliance on linear dose-response models,
as prescribed by the agency's 1986
Guidelinesfor Carcinogen Risk Assessment.
This document directed risk assessors to
assume that any exposure to a chemical
carcinogen, no matter how low, was asso-
ciated with some degree of measurable
cancer risk.
The EPA's more current thinking in
this area is reflected in the Proposed
Guidelinesfor Carcinogen Risk Assessment,
the 1996 draft update to the 1986 guide-
lines. These new guidelines shift the focus
of cancer risk assessment away from
default assumptions on linearity toward
an emphasis on mechanisms ofaction and
a description of the conditions under
which carcinogenic hazards are likely to be
expressed. Under the new guidelines, the
EPA is obligated to consider mechanistic
data in the setting ofregulatory goals and
standards and, if warranted, to depart
from assumptions of linearity in the set-
ting ofthese regulatory values. As with the
1986 version, the 1996 guidelines were
designed to advise risk assessors in both
the laboratory and the field as to EPA pol-
icy regarding carcinogenic chemicals, and
to provide guidance for those who advise
decision makers and the public on the
associated risks.
Chloroform appeared to be a good test
candidate upon which the EPA could try
out its new cancer risk assessment policies.
An emerging body of evidence suggested
that chloroform could produce tumors in
animals only if the exposures exceeded a
critical threshold dose preceded by obvi-
ous signs of toxicity. Based on these find-
ings, some scientists suggested that chlo-
roform was a nonlinear threshold carcino-
gen, meaning that there might be a level
below which a person could be exposed to
chloroform without the threat of cancer.
But because the 1986 guidelines provided
minimal guidance on how to use nonlin-
ear dose-response data in the risk charac-
terization process, efforts to revise regula-
tory policies for chloroform (or any other
carcinogen, for that matter) based on
mechanistic data were essentially stalled.
With the release of the draft 1996 guide-
lines, proponents of a revised regulatory
strategy for chloroform perceived a win-
dow ofopportunity. By proposing to raise
the MCLG for chloroform to 300 ppb,
the EPA was opening a dialogue among
stakeholders and possibly setting a prece-
dent for the future evaluation ofchemical
carcinogens based on mechanistic data.
But the dialogue that ensued proved
highly contentious. As news ofthe propos-
al spread throughout the public health and
environmental community, scientists and
advocates immediately issued an appeal to
the EPA, claiming that chloroform's status
as a threshold carcinogen in humans
remained uncertain and demanding that
the agency retain the existing health goal.
To provide a forum on the issue, the
EPA's Office ofWater hosted a workshop
in June 1998 in Washington, DC, and
invited stakeholders to attend. The sharp
nature of the disagreement among scien-
tists on both sides of the issue was soon
apparent; later in the year, the agency
decided to drop the proposal from its final
disinfectants and disinfection by-products
(DBPs) rule for drinking water (which was
issued on 16 December 1998), pending
additional review.
The decision to abandon the revised
goal and retain a linear approach led to a
concerted lobbying and letter-writing cam-
paign among industry representatives hop-
ing for congressional support, and industry
accusations that the EPA had succumbed
to political pressure. That same month, a
coalition comprising the Chlorine
Chemistry Council and the Chemical
Manufacturers Association (two industry
trade organizations based in Arlington,
Virginia) and a group of 11 water utility
companies sued the EPA, claiming the
agency had violated provisions of the
SDWA by failing to set the standard for
chloroform using the best available science.
Two public interest groups, the Natural
Resources Defense Council and Physicians
for Social Responsibility, have since inter-
vened in the lawsuit.
How the chloroform debate plays out is
seen as a critical issue that will define policy
under both the draft cancer guidelines and
the SDWA. For these reasons, it is being
watched closely by major research and poli-
cy organizations and high-level government
offlcials, even at the level ofVice President
Al Gore's office. According to Jeanette
Wiltse, director of the Health and
Ecological Criteria Division in the Office
ofScience and Technology in the Office of
Water, the EPA Science Advisory Board
will begin reviewing the chloroform risk
assessment this summer. Pending the
results ofthat evaluation, a revised MCLG
for chloroform may yet see the light ofday.
Says Wiltse, "Chloroform is a stalking-
horse for how we're going to do cancer risk
assessment. Everything has come down to
arguing about chloroform, but to me the
real debate is how we're going to deal with
new evidence about how carcinogens cause
their effects."
Disagreements over Data
The proposed MCLG was based on a 1997
EPA- and industry-sponsored study titled
An Evaluation ofEPA's Proposed Guidelines
for Carcinogen Risk Assessment Using
Chloroform and Dichloroacetate as Case
Studies: Report ofan Expert Panel, which
was conducted by the International Life
Sciences Institute (ILSI), an international
nonprofit research institute based in
Washington, DC. The ILSI panel com-
prised 10 expert scientists from academia,
industry, and government, and was chaired
by Melvin Anderson of ICF-Kaiser
International. In addition to EPA support,
a portion of ILSI's funding came from
industry groups, including the Chlorine
Chemistry Council. Following its review,
ILSI concluded that chloroform is
nongenotoxic (does not react with DNA)
and that cytotoxicity and regenerative cell
proliferation are obligatory precursors to
chloroform-induced liver and kidney
tumors in mice and rats. The EPA tenta-
tively concurred and proposed basing the
MCLG on the reference dose for liver toxi-
city under the assumption that protection
against that noncarcinogenic outcome
would automatically protect against cancer,
which could only occur at a higher dose.
What neither the ILSI panel nor the
EPA considered adequately, say opponents
to the measure, are "literally dozens" ofepi-
demiological studies suggesting that chloro-
form in drinking water causes cancer.
Chloroform is one of a group of chlorina-
tion by-products in drinking water.
Epidemiological studies ofchloroform have
been controversial because the chemical is
always present in water supplies along with
brominated compounds such as bro-
modichloromethane (BDCM) and
chlorodibromomethane (CDBM), which
are both suspected genotoxic carcinogens in
animals. All three compounds are included
in a group of drinking water contaminants
collectively known as trihalomethanes
(THMs), which are regulated by the EPA as
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a group with a combined MCL of 100 ppb
(an MCL of 80 ppb is on the books but is
not enforceable until 2001). Given that
BDCM has been shown to produce tumors
in multiple organ systems in several animal
models, it is regulated as a carcinogen by the
EPA and has an MCLG of zero. The evi-
dence for CDBM is less conclusive, however,
and it is not regulated as a carcinogen. The
EPA has assigned it an MCLG of60 ppb.
Hundreds of other chemical com-
pounds are also commonly found in drink-
ing water, which also complicates findings.
"Epidemiology has the advantage of study-
ing people," says Rory B. Conolly, a senior
scientist at the Chemical Industry Institute
of Toxicology, a toxicology research orga-
nization based in Research Triangle Park,
North Carolina. "The disadvantage is that
there's no such thing as a cohort exposed
exclusively to chloroform."
However, opponents to the measure are
not to be deterred; they point to a nuniber
ofstudies they believe show convincing evi-
dence that chloroform causes cancer.
Among these are a 1992 meta-analysis by
Robert D. Morris, an associate professor in
the Department of Family Medicine and
Community Health at the Tufts University
Medical School in Boston, published in the
July 1992 issue of the American Journal of
Public Health, which found that 4,300 cases
of bladder cancer and 10,000 total com-
bined cancer cases could be attributed to
chlorination by-products in drinking water.
Opponents also point to a study published
in the July 1997 issue of the American
JournalofPublic Health by Timothy Doyle,
a researcher in the Division of
Epidemiology at the School of Public
Health at the University of Minnesota in
Minneapolis. Doyle's study concluded that
Iowa women living in areas supplied by
municipal water systems containing higher
concentrations ofchloroform were at signif-
icant risk for both colon cancer and total
combined cancers. Because chloroform con-
centrations in water tested in the study were
rarely elevated beyond 100 ppb, Doyle was
unable to quantify risks above that level.
Ronald Melnick, a toxicologist with the
NIEHS and a critic of the EPA's revised
goal, asks, "When there's measurable risk at
levels below 100 ppb, how can the EPA jus-
tify a goal of300 ppb?"
The EPA counters that it reviewed both
studies, along with many others, but
remains unconvinced. "We did review the
epidemiology data," says Wiltse, "but none
of the analyses were more than suggestive,
although there were some odds ratios that
were greater than one." Moreover, she
adds, "The studies were of disinfected
water, which contains hundreds of chemi-
cals, not chloroform alone. Chloroform
was simply measured in the Doyle study as
an indicator of disinfection." In the 31
March 1998 Notice of Data Availability,
the EPA pointed out that some positive
associations were beset by confounding
variables such as smoking, and that results
often conflicted with respect to specific
sources of exposure. Furthermore, the EPA
disagreed with the approach used by
Morris, which produced only single
numerical estimates of risk, and instead
used a set of the most appropriate studies
to conduct a distributional "population
attributable risk" (PAR) analysis that pre-
dicted that between 1,100 and 9,300 cases
of bladder cancer might be associated with
DBPs annuially. PAR methodology, which
presents a range of potential risks to popu-
lations rather than a single estimate, is
often used by epidemiologists to provide a
perspective on the potential magnitude of
risks associated with various exposures.
Critics of the PAR approach point to the
conspictiotis absence of any end points
other than bladder cancer and add that
despite the EPA's dismissal of the Morris
data, its estimated range for annual bladder
cancers captured the Morris study point
estimate of 4,300 cases and its upper
bound estimate of 9,000 approached the
Morris estimate for all cancers combined.
In other words, regardless ofthe differences
in methodology, both studies arrived at
essentially the same numerical estimate of
the risk ofbladder cancer from exposure to
DBPs in drinking water. "So why all the
sound and fury about the Morris study
being unreliable?" asks Erik Olson, a senior
attorney with the Natural Resources
Defense Coouncil.
Focus on Animal Studies
Proponents of a revised MCLG say the
epidemiological associations should be
viewed in light of toxicological evidence
suggesting that cancer can be induced only
with extremely high exposures that are
often cytotoxic in target organs. Studies in
several species of mice and rats support
this view. In most cases, only concentrat-
ed, repeated doses, such as those produced
by gavage, have proven effective.
However, critics remain skeptical and sug-
gest that chloroform carcinogenicity at
doses below those causing cytotoxicity and
regenerative cell proliferation isn't well
characterized. Melnick, in particular, has
found that low-dose exposures to bromi-
nated THMs including BDCM and
DBCM can produce liver tumors in
female mice with no effect on liver toxicity
or hepatocyte proliferation. Whether chlo-
roform is similarly capable, he says, is not
certain, but he adds that there is cause for
concern, given that chloroform anid the
brominated THMs all break down to the
same genotoxic intermediate (phosgene).
Ironically, the proposal to set the
MCIG for chloroform alone at 300 ppb is
practically a moot point because the
enforceable MCI for THMs as a group.
including chloroform, is only 100 ppb.
Because chloroform is seen as an indicator
compound for drinking water IRHMs,
actually detecting it at 300 ppb would
mean that the MCL had been exceeded and
that the water supply was in violation of
the standard. But the goal of 300 ppb is
especially desirable to drinking water sup-
pliers, who see it as more readily aiclhies-
able. Exactly how the EPA plans to recon-
cile the difference between the two stani-
dards remains uincertain.
George 1ticier, director of the
Environmental Toxicology Progranm at the
NIEHS, says there's no doubt that the EPA
will adopt a nonlinear approach for somile
carcinogens as it works its way througlh the
1996 cancer guidelines, which will likely be
finalized this fall. "They may Ultirnately
adopt such an approach for chloroform,"
he says. But Lucier concedes that chloro-
form studies have yielded some ambiguous
data. "I think it was a close call," he says. "I
can see how people would differ on which
approach to use."
In any event, the whole issue is still an
open book, and the value that the chloro-
form MCLG will ultimately be assigned
remains to be seen. According to Wiltse,
the original proposal of 300 ppb has
already been abandoned as the EPA has
begun considering additional source contri-
butions for chloroform that include inhala-
tional and dermal exposures. Incorporating
these pathways into the risk equation has
yielded revised estimates for the MC,G of
between 60 and 70 ppb. Says Lucier. "This
is a prototypical issue, more a matter of
principle than of safe exposuLc levels.
Industrv would like to see the FPA imple-
ment the revised guidelines. It wouldn't
take much more evidence to support a
nonlinear approach for chloroform."
Charles W. Schmidt
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